Company: BSX
Filing Date: 2025-02-26
Form Type: 8-K
Source: 0000885725-25-000013
Chunk: 0

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-26
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On February 21, 2025, Boston Scientific Corporation (the “ Company”), as guarantor, and American Medical Systems Europe B. V. (“ AMS Europe”), its wholly owned finance subsidiary, as issuer, entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated February 21, 2025, the “ Underwriting Agreement”), among the Company, AMS Europe and the several underwriters named in the Underwriting Agreement (the “ Underwriters”), in connection with AMS Europe’s previously announced pricing of €1,500,000,000 aggregate principal amount of its senior notes. Pursuant to the Underwriting Agreement, the Underwriters agreed to purchase €850,000,000 in aggregate principal amount of 3.000% Senior Notes due 2031 and €650,000,000 in aggregate principal amount of 3.250% Senior Notes due 2034 (collectively, the “ Notes”) under the shelf registration statement on Form S-3 of the Company and AMS Europe (File No. 333-285032). The Notes are fully and unconditionally guaranteed by the Company. The Underwriting Agreement contains customary representations, warranties and agreements of the Company and AMS Europe and customary conditions to closing, indemnification rights and obligations of the parties and termination provisions. The Underwriters and their affiliates have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with and perform services for the Company and AMS Europe in the ordinary course of their business.

The Notes were issued pursuant to an indenture dated as of March 8, 2022 among AMS Europe, the Company and U. S. Bank Trust Company, National Association, as trustee (the “ Indenture”). The Indenture contains covenants that restrict (i) the Company’s and AMS Europe’s ability, with certain exceptions, to merge or consolidate with another entity or transfer all or substantially all of its property and assets, and (ii) the Company’s and its Subsidiaries (as defined in the Indenture) ability, with certain exceptions, to incur liens. These covenants are subject to important exceptions and qualifications, as described in the Indenture. The Indenture also provides for customary events of default. Additional terms of the Notes are set forth in the forms of notes